Rezolve AI PLC enters the final days of May with a sharp tension at its core: the stock is up 13% on the week to $2.98, yet the borrow market is close to fully shut, short interest runs above a fifth of the free float, and cost to borrow has more than doubled in a month.
The lending picture is the most striking element right now. Availability has collapsed to just 0.9% of short interest — meaning there is effectively one share left available to borrow for every 111 already out on loan. That is the tightest the market has been in weeks, and it sits close to the 52-week minimum of 0.28%. Cost to borrow has climbed to 17.9% annualised, up from around 7% in late April — a 157% rise over the month. Short interest itself is 21.8% of the free float by ORTEX estimates, up roughly 3 percentage points from early May levels and approaching the late-April high of 22.5%. With borrow this scarce, new short sellers face a very high cost of entry, and existing positions become increasingly expensive to maintain.
The ORTEX short score reinforces this picture. It has risen every session this week, reaching 77.2 on May 28 — up from 73.9 at the start of the month and the highest reading in the 30-day window. The factor rank places RZLV in the 2nd percentile of short score across the market, effectively flagging it as one of the most aggressively short-positioned names on the platform. Days to cover of 2.86 is modest in absolute terms, but given how little borrow remains, the margin for short-side manoeuvre is narrow.
Options tell a calmer story than the lending market. The put/call ratio is 0.27, close to its 52-week high of 0.28, but the 20-day mean is 0.25 and the z-score is less than one standard deviation above it. That means options positioning is not sounding alarm bells — traders are not piling into puts, and there is no evident rush for downside protection. The PCR has trended gradually higher through May from the 0.21–0.22 range in late April, but the move is measured rather than panicked.
The ownership and insider picture is worth noting for a stock of this size. Founder and Chairman/CEO Daniel Wagner bought over 800,000 shares at $4.00 on April 2, spending roughly $3.25 million across two transactions. Director Stephen Perry added a further 95,600 shares at $2.78 on May 13. Total net insider buying over the past 90 days comes to approximately 908,500 shares worth $3.5 million — meaningful for a company with a market cap near $1.2 billion. The top institutional register is concentrated: Dblp Sea Cow Limited holds 11.98% of shares, and BlackRock added 2.04 million shares as of the April 30 reporting date. The ownership base is thin — just 93 institutional holders on record — which amplifies the potential impact of any flow shift.
On fundamentals, the company remains loss-making. Estimated net income is negative $58 million against estimated revenue of $357 million. The EV/EBITDA multiple is deeply negative. The stock's ORTEX Growth score ranks at a strong 91.2 percentile, but Quality and Value scores sit below 25 — the business is being valued almost entirely on revenue trajectory, not on profitability or balance-sheet strength. Peers in the AI and technology space had a mixed week: AISP surged 29% on the week and BTQ jumped 45%, while LQWD fell 13% — the peer cohort is volatile and directionally scattered, offering little read-through.
The next earnings event is scheduled for June 26. The four most recent post-announcement sessions produced moves of -0.8%, +5.0%, -11.8%, and +7.1% on day one — a wide range with no consistent pattern. With availability this tight and short interest this elevated, the setup into that date is one to watch closely.
See the live data behind this article on ORTEX.
Open RZLV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
